State Policy Landscape to Address the Opioid and Overdose Crisis in 2024
Introduction

Ken Shatzkes, PhD
Program Director
Foundation for Opioid Response Efforts

Follow ongoing updates on our website:
https://www.ForeFdn.org
Agenda

1. Introduction and Webinar Logistics

2. Challenges and Opportunities in State Policy to Address the Opioid and Substance Use Crisis
   Katie Greene, MPP - Project Director, Public Health, National Academy for State Health Policy (NASHP)

3. The Evolving Opioid Crisis and Policy Environment: State Policy Opportunities
   Bradley Stein, MD, PhD - Director of the Opioid Policy, Tools, and Information Center (OPTIC), RAND Corporation

4. Fireside Chat
   Chinazo Cunningham, MD - Commissioner, New York State Office of Addiction Services and Supports (OASAS)

   Douglas Huntsinger - Executive Director for Drug Prevention, Treatment and Enforcement and Chairman of the Indiana Commission to Combat Substance Use Disorder

   Karen A. Scott, MD, MPH - President, FORE

5. Question and Answer Session
Webinar Logistics

1. The webinar is being recorded and will be available on [www.ForeFdn.org](http://www.ForeFdn.org) shortly after the session ends.

2. Presentation slides will be made available for download on our website.

3. Please use the “Q&A” found at the bottom of your Zoom screen.
   - If you have a similar question, please upvote using the thumbs up button on the question.
   - We will read as many questions live as time permits.

4. There will be a brief survey immediately following the webinar. Please provide us with feedback!
About FORE

Founded in 2018, the Foundation for Opioid Response Efforts (FORE) is a 501(c)(3) private, national, grantmaking foundation focused on one urgent public health emergency – the opioid crisis.

Vision
To inspire and accelerate action to end the opioid crisis

Mission
To convene and support partners advancing patient-centered, evidence-based solutions addressing the opioid crisis

Focus
With patients at the center, our focus includes:

- Professional education
- Payer & Provider strategies
- Policy initiatives
- Public awareness
Webinar Speakers

FORE Grantees

Katie Greene, MPP
*Project Director, Public Health National Academy for State Health Policy (NASHP)*

Bradley Stein, MD, PhD
*Director of the Opioid Policy, Tools, and Information Center (OPTIC) RAND Corporation*

Chinazo Cunningham, MD
*Commissioner New York State Office of Addiction Services and Supports (OASAS)*

Douglas Huntsinger
*Chairman Indiana Commission to Combat Substance Use Disorder*
Challenges and Opportunities in State Policy to Address the Opioid and Substance Use Crisis

Katie Greene, MPP
Project Director, Public Health
National Academy for State Health Policy (NASHP)
About NASHP

- The National Academy for State Health Policy (NASHP) is a not-for-profit organization committed to developing and advancing state health policy innovations and solutions.

- NASHP provides a unique forum for the productive exchange of strategies across state government, including the executive and legislative branches.

- To improve the health and well-being of all people across every state.

- To be of, by, and for all states by providing nonpartisan support for the development of policies that promote and sustain healthy people and communities, advance high quality and affordable health care, and address health equity.
# How NASHP Accomplishes Our Mission

<table>
<thead>
<tr>
<th>Health and Human Services Secretaries</th>
<th>Medicaid Directors</th>
<th>Behavioral Health Directors</th>
<th>Insurance Commissioners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Governor's Advisors</td>
<td>State Legislators</td>
<td>Medical Directors</td>
<td>Title V &amp; CYSHCN Directors</td>
</tr>
<tr>
<td>State Based Marketplaces</td>
<td>Health Equity Officers</td>
<td>Career and Program Staff</td>
<td>Aging and Disability Directors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Public Health Directors</td>
</tr>
</tbody>
</table>
How NASHP is supporting state leaders in addressing the opioid and overdose crisis

NASHP is working with state leaders across policy landscapes to enact and expand policies that can enhance access and outcomes for Substance Use Disorder (SUD) and Opioid Use Disorder (OUD) treatment. Key activities include:

- **Forums for state-to-state learning**: The state opioid settlement (SOS) learning network is an ongoing forum for state-to-state learning and discussion of promising practices for settlement administration.

- **Advancing Evidence-Based Strategies**: NASHP develops resources for state policymakers to help advance strategies for reducing opioid-related overdoses and advancing evidence-based SUD treatment.

- **Tracking state policies**: NASHP provides timely tracking and analysis of state opioid settlement activities and other policy topics.

- **Technical assistance and support**: NASHP provides technical assistance to state leaders confronting emerging and ongoing challenges.
State Health Priorities – 2024-2025

- Health Care Workforce
- Behavioral Health
- Cost and Value of Health Care
- Social Drivers of Health
- Maternal Health
- Aging
- Public Health
- Medicaid Unwind
Trends in substance use:
responding to a shifting crisis

Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021

Fentanyl mixed with cocaine or meth is driving the ‘4th wave’ of the overdose crisis

Addiction, Volume: 118, Issue: 12, Pages: 2477-2485, First published: 13 September 2023, DOI: (10.1111/add.16318)
Youth overdoses have increased, even as substance use continues to decrease

- Youth substance use at historically low levels
- Yet, overdose deaths among youth continue to go up – driven by proliferation of fake pills that contain illicit fentanyl
  - Median monthly overdose deaths among persons aged 10–19 years increased 109% from 2019-2021; deaths involving illicitly manufactured fentanyls (IMFs) increased 182%. (CDC MMWR)

Sources:
- Monitoring the Future Survey 2023 https://monitoringthefuture.org/results/annual-reports/
- Chris Jones (SAMHSA) presentation to State Opioid Settlement Learning Network 3/1/2024
Rising disparities in opioid-related harms

Health disparities in overdose rates continue to worsen, particularly among Black and AI/AN persons.

Social determinants of health, such as income inequality, exacerbate these inequities.

Solutions: Implementation of culturally responsive overdose prevention and response efforts that meet needs of impacted communities.
Key opportunity: Harnessing momentum around HRSN

Health Related Social Needs

- Target populations: health and social risk criteria
- Covered benefits:
  - Housing supports
  - Nutrition supports
  - Case management, outreach, and education
  - Infrastructure and capacity building
- In 2022 - 2024, AZ, AR, CA, MA, NJ, NY, OR, and WA received approval of section 1115 demonstration waivers
- Pending waivers from: HI, IL, ME, MT, NM, RI, WV

Supports for people with SUD/OUD

- Arizona’s Housing and Health Opportunities (H2O) Demonstration targets individuals experiencing/at-risk of homelessness with at least one of a series of health and social conditions or circumstances, which includes individuals in need of substance use treatment
1115 Waivers Cont’d: Re-entry

Reentry in Correctional Settings

• Up to 90 days of in-reach services to support transitions to the community
  o Case management
  o Clinical consultations
  o Medications (incl. MOUD)
  o Community Health Worker services
• CA, MT, WA received section 1115 demonstration waivers
• Pending waivers from: AZ, HI, IL, KY, MA, MT, NH, NJ, NM, NY, NC, OR, RI, UT, VT, WV

Supports for people with SUD/OUD

• **California** and **Washington** 1115 waivers authorize the states to cover MAT for all types of SUD with accompanying counseling
• Via California’s Providing Access and Transforming Health (PATH) Justice-Involved initiative, the state is providing small planning grants to correctional agencies to support planning and implementation of re-entry services
Key opportunity: modernizing behavioral health systems

- Investing in the crisis continuum
- Expansion of Certified Community Behavioral Health Clinics (CCBHCs)
- Housing supports for people with SUD/SMI
- Braiding funding to address OUD/SUD and Mental Illness:
  - State Opioid Response (SOR)
  - Community Mental Health Services Block Grant (MHGB)
  - Substance Use Prevention, Treatment, and Recovery Services Block Grant (SUBG)
Key opportunity: lower barriers to treatment and harm reduction services

New flexibilities for MOUD and naloxone
- New Methadone rules promote greater flexibility
- Removal of x-waiver requirements for buprenorphine
- OTC naloxone

Priorities at the state level:
- Assessing regulatory barriers at the state level
- “No wrong door:” prioritizing initiation of MOUD in correctional, community, emergency department settings
- Working with harm reduction partners and advancing “low barrier” models of care
Key opportunity: adapting strategies to an evolving crisis

- Investing in the continuum of prevention strategies (primary, secondary, tertiary)
- Examining legal frameworks for harm reduction (Good Samaritan laws, fentanyl test strips, syringe and paraphernalia laws)
- Adapting harm reduction approaches to changes in the drug supply and other trends
  - Drug checking (including fentanyl and xylazine test strips), improved surveillance tools
  - Build community-based harm reduction infrastructure and communication with organizations serving people who use drugs
- Medicaid contingency management waivers
  - Section 1115 waivers approved in Washington and California (Delaware and West Virginia pending)
Thank you!

Katie Greene
kgreene@nashp.org
The Evolving Opioid Crisis and Policy Environment: State Policy Opportunities

Bradley Stein, MD, PhD
Director of the Opioid Policy, Tools, and Information Center (OPTIC)
RAND Corporation
Today’s Talk

• Learning from state policy responses to the outbreak of COVID
• Questions emerging from the shifting policy landscape and evolving opioid crisis
• Identifying opportunities for state policy interventions
Pandemic triggered policy changes that influenced how we address the opioid crisis

- **Telehealth policies**: payment parity, initiating buprenorphine
- **Relaxed policies**: authorizing treatment by out-of-state clinicians, temporary licenses
- **Substance use disorder (SUD) treatment policies**: prior authorization changes, waived copayments, less drug screening
- **Liberalized**: Medicaid eligibility and methadone policies
Effect on Medication Treatment for Opioid Use Disorder seemed positive

- Medication treatment for opioid use disorder (MOUD) was relatively stable in first year of COVID, while other elements of outpatient care declined
- Studies suggest telehealth facilitated access for those receiving treatment
- Both patients and providers like aspects of telehealth—e.g. ease of access, more accessible for many patients
- Less burdensome access to methadone not associated with increased diversion or fatal opioid overdose
But story of policy effects may be more nuanced

- Many Opioid Treatment Programs (OTPs) did not make use of liberalized methadone take-home policies
- Despite attention to telehealth, only a minority of patients received buprenorphine treatment via telehealth in Medicaid, Medicare, and commercially insured populations
- Only about 10% of new buprenorphine episodes among commercially insured and Medicare Advantage beneficiaries were initiated via telehealth
- How were changes in buprenorphine prescribing episodes associated with state telehealth policies?
Changes in initiating and ending buprenorphine episodes during COVID

- Used national pharmacy data on buprenorphine dispensed from >90% of retail pharmacies to examine overall buprenorphine episodes, episodes starting, episodes ending, and duration of episodes initiated immediately before public health emergency
- Examined association of state policies with buprenorphine episode characteristics
  - Initiating buprenorphine via telehealth
  - Payment parity for telehealth in both Medicaid and commercial populations
  - Allowing telehealth for behavioral health disorders
  - Banning Medicaid prior authorization for substance use disorder treatment
  - Allowing physicians to practice across state lines
  - Allowing psychologists to practice across state lines
Buprenorphine episodes in 2020 after COVID

• Overall number of buprenorphine episodes during pandemic remained relatively stable
  • Substantial increase in Medicaid episodes, decrease in cash-pay

• But 17% fewer new buprenorphine episodes than expected in 2020 compared to 2019; comparable decreases in episodes ending

• At population level, telehealth policies not associated with change in overall buprenorphine treatment episodes: state with multiple telehealth policies had some shifts in episodes beginning and ending

• State allowing psychology interstate practice associated with longer buprenorphine treatment episodes
Why didn’t telehealth have population-level effect?

- Telehealth may be beneficial to patients receiving buprenorphine via telehealth, but relatively few patients receive buprenorphine treatment via telehealth.
- Telehealth may shift which individuals receive care or nature of care provided but not change care at the population level.
- Other contemporaneous changes in policies or society may have influenced care provided.
- Understanding these nuances can better inform future policymaking.
What about Medicaid unwinding?

- Medicaid is country’s largest payer for substance use treatment
- Expansion under Affordable Care Act increased number of individuals with SUD receiving treatment/buprenorphine paid for by Medicaid
- States required to maintain Medicaid enrollment during COVID
- Continuous enrollment requirement has ended with wide state variation in disenrollment
- Early stories of deleterious impact of Medicaid unwinding on those receiving treatment for OUD/SUD
Story of Medicaid unwinding may also be nuanced

- COVID-related policies were important benefit for many, helping them use insurance coverage to stay in SUD treatment
- Likely responsible for substantial shift to Medicaid among those receiving buprenorphine treatment; may have contributed to longer treatment episodes
- Population-level effects less clear – e.g. were longer treatment episodes an unintentional barrier to those trying to start treatment?
- Hard to imagine unwinding won’t harm some people, but how and for whom will harm be greatest?
- New FORE project examines these issues, informing policies to mitigate consequences of unwinding for those receiving MOUD
Rapidly changing environment may give states policy opportunities

SAMHSA changing policy to facilitate access to Methadone
  • Variable uptake of new policy
  • Who benefits?
  • Possible unintended consequences?

No more X-waiver for buprenorphine prescribing but to what effect?
  • Initial studies suggest modest impact of removing this barrier
  • ~ 70% of clinicians stop prescribing after several months, only 10% treated more than 10 patients per month over 6 years
  • How can we facilitate and support clinicians willing to treat more patients?

Xylazine growth: when injected, this veterinary sedative causes necrotic wounds.
  • Test strips could help identify its presence in mixes with other drugs
Other State Policy Opportunities

We don’t have medications for substances other than opioids

- Evidence that Contingency Management works but federal restrictions limit its use
- Feds are starting to relax limits
  - Contingency management used in Veterans Affairs healthcare system as primary treatment for stimulant use disorder
  - Several states have received CMS waivers to increase use of Contingency Management
- Office of Inspector General has announced intention to create a safe harbor provision for Contingency Management
Opioid crisis is evolving — so must our responses to it
Implementing policies to address the polysubstance crisis will require incremental gains, emerging understanding, and ongoing policy corrections. Lots of opportunities for impactful state policies.
Thank you

Bradley D. Stein
stein@rand.org

Opioid Policy Tools and Information Center
NIDA P50DA046351

OPTIC website
Fireside Chat

Chinazo Cunningham, MD
Commissioner
New York State Office of Addiction Services and Supports (OASAS)

Douglas Huntsinger
Chairman
Indiana Commission to Combat Substance Use Disorder
DHuntsinger@gov.in.gov

Karen A. Scott, MD, MPH
President
FORE
Question and Answer Session

FORE Grantees

Katie Greene, MPP
Project Director, Public Health
National Academy for State Health Policy (NASHP)

Bradley Stein, MD, PhD
Director of the Opioid Policy, Tools, and Information Center (OPTIC)
RAND Corporation

Chinazo Cunningham, MD
Commissioner
New York State Office of Addiction Services and Supports (OASAS)

Douglas Huntsinger
Chairman
Indiana Commission to Combat Substance Use Disorder
Take Care of Yourself!
Thank You For Your Work!